Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1482388 | 0.85 | GPR84 (0.33) | MEN1KMT2AMLYCDSLC1A2 | |
| Trifluoroacetic Acid SCHEMBL1097511 | 0.79 | LMNA (0.35) | MEN1KMT2AMLYCDALDH1A1TDP1 | |
| Trifluoroacetic Acid SCHEMBL27762565 | 0.79 | TSHR (0.39) | MEN1KMT2AMLYCDSLC1A2 | |
| Acetic Acid SCHEMBL3314659 | 0.77 | — | — | |
| Trifluoroacetic Acid SCHEMBL31570038 | 0.76 | CYP1A2 (0.37) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL28832532 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL11509703 | 0.76 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL11404300 | 0.76 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL30054036 | 0.76 | TSHR (0.58) | MEN1KMT2AMLYCD | |
| Trifluoroacetic Acid SCHEMBL4007868 | 0.76 | LMNA (0.40) | MEN1KMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1988899-B | euphorbia lunulata extract, and preparation method and application thereof | UNIV NIHON | 2011-07-06 | — | — | CN | claimed |
| CN-1988899-A | Euphorbia lunulata extract, and preparation method and application thereof | UNIV NIHON (JP) | 2007-06-27 | — | — | CN | claimed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240115679-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-04-11 | — | — | US | disclosed |
| US-11833196-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023097194-A2 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-11219673-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-11 | — | — | US | disclosed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180078625-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-22 | — | — | US | disclosed |
| EP-3273944-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-3266444-A1 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2018-01-10 | — | — | EP | disclosed |
| EP-2538919-A2 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | disclosed |
| CN-102471347-A | Enantiomers of spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2012-05-23 | — | — | CN | disclosed |
| EP-2448943-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011106729-A2 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-09-01 | — | — | WO | disclosed |
| CN-1988899-B | euphorbia lunulata extract, and preparation method and application thereof | UNIV NIHON | 2011-07-06 | — | — | CN | disclosed |
| WO-2011002708-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-30 | — | — | US | disclosed |
| US-20100168415-A1 | Process for preparation of Caspofungin acetate | LEE KWANG-CHUNG | 2010-07-01 | — | — | US | disclosed |
| CN-1988899-A | Euphorbia lunulata extract, and preparation method and application thereof | UNIV NIHON (JP) | 2007-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV1, TRPV5, TRPV3 | MEN1 4044/4885KMT2A 3548/4885MLYCD 4643/4885 |
| US-20100168415-A1 | Process for preparation of Caspofungin acetate | NAT1, CASP1, CASP14 | MEN1 952/4885KMT2A 3835/4885MLYCD 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.